Extracellular DNA—A Danger Signal Triggering Immunothrombosis

Chongxu Shi 1*, Luying Yang 1, Attila Braun 2 and Hans-Joachim Anders 1

1 Renal Division, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians University Munich, Munich, Germany, 2 German Center for Lung Research, Walther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilians University Munich, Munich, Germany

Clotting and inflammation are effective danger response patterns positively selected by evolution to limit fatal bleeding and pathogen invasion upon traumatic injuries. As a trade-off, thrombotic and thromboembolic events complicate severe forms of infectious and non-infectious states of acute and chronic inflammation, i.e., immunothrombosis. Factors linked to thrombosis and inflammation include mediators released by platelet granules, complement, and lipid mediators and certain integrins. Extracellular deoxyribonucleic acid (DNA) was a previously unrecognized cellular component in the blood, which elicits profound proinflammatory and prothrombotic effects. Pathogens trigger the release of extracellular DNA together with other pathogen-associated molecular patterns. Dying cells in the inflamed or infected tissue release extracellular DNA together with other danger associated molecular pattern (DAMPs). Neutrophils release DNA by forming neutrophil extracellular traps (NETs) during infection, trauma or other forms of vascular injury. Fluorescence tissue imaging localized extracellular DNA to sites of injury and to intravascular thrombi. Functional studies using deoxyribonuclease (DNase)-deficient mouse strains or recombinant DNase show that extracellular DNA contributes to the process of immunothrombosis. Here, we review rodent models of immunothrombosis and the evolving evidence for extracellular DNA as a driver of immunothrombosis and discuss challenges and prospects for extracellular DNA as a potential therapeutic target.

Keywords: thrombosis, leukocytes, platelets, vasculitis, mouse model, stroke, sepsis

INTRODUCTION

Evolution positively selected four major danger response programs, i.e., inflammation, clotting, epithelial healing, and mesenchymal healing because they assure survival upon traumatic injury (1). Blood clotting and inflammation are early responses that immediately create barriers. Clotting creates an inside-out barrier for blood loss and clotting and inflammation both create an outside-in barrier for pathogen entry. Balanced clotting can prevent fatal bleeding and balanced inflammation can prevent fatal sepsis. However, trade-offs exist and largely contribute to prevalent disease pathomechanisms in clinical medicine (2). Thrombotic and thromboembolic events are important complications in severe forms of infectious and non-infectious states of acute and chronic inflammation, i.e., immunothrombosis (3). Proinflammatory mediators released from platelets, complement, and lipid mediators link clotting and inflammation as do certain integrins, and neutrophil extracellular traps (NETs).

As a novel entry, extracellular deoxyribonucleic acid (DNA) can elicit profound proinflammatory and pro-thrombotic effects in the extracellular space (4). Pathogens release...
DNA together with other pathogen-associated molecular patterns (PAMPs). Dying parenchymal cells release extracellular DNA together with other danger- or damage-associated molecular patterns (DAMPs) and neutrophils release DNA by forming neutrophil extracellular traps (NETs) during infection, trauma or other forms of vascular injury (5–7). Extracellular DNA localizes to the sites of injury and experimental studies employing deoxyribonuclease (DNase)-deficient mouse strains or recombinant DNase demonstrate a functional contribution of this extracellular DNA to the development of immunothrombosis.

In this review, we summarize basic knowledge about the process of immunothrombosis, and discuss the role of extracellular DNA as a modulator of thrombosis in the arterial and venous segments of the vasculature. Furthermore, we describe several mouse models to study the process of immunothrombosis in different disease settings.

**Experimental Models of Venous Thrombosis**

Venous thrombosis is a common clinical health care problem and causes congestion and pain when affecting the deep veins of the limbs or acute thoracic pain, dyspnea, and shock when affecting the pulmonary arteries. Pulmonary embolism is a severe life-threatening complication of deep vein thrombosis. Venous thrombosis frequently develops in the perianal venous plexus region and usually presents as painful swelling at the site of the blood clot. The most popular rodent model of venous thrombosis is occlusion of the inferior vena cava via a surgical intervention, which generates clots of sufficient size for measuring clot weight and for histopathological characterization of the clot material (8).

Here, we introduce several types of venous thrombosis models which are studied in mice (Table 1).

**Inferior Vena Cava Stasis Occlusion Model**

The stasis occlusion variant is a model of permanent inferior vena cava (IVC) ligation, mimicking the clinical condition of complete vascular occlusion. Technically, the IVC and all collateral side branches distal to the left renal vein are ligated. Thrombus formation in this model involves venous stasis and local release of tissue factor (TF) with augmented coagulation inside the IVC (9, 80). The advantages of this model are its low mortality, high frequency of thrombus generation, and highly consistent thrombus sizes (10, 11). Ultrasound can sequentially monitor thrombus progression and to select an optimal time point for harvesting the thrombus. This model has proven valuable to study the interactions between the venous wall and thrombus progression from acute (first 2–3 days) to chronic inflammation as well as to study the subsequent remodeling of the venous wall (12, 13). As a relevant discrepancy to most venous thromboses in human, blood flow does not establish. Peternel et al. used the stasis occlusion model in rats and found it well-suited for evaluating antithrombotic therapies (14).

**Inferior Vena Cava Stenosis Model**

Partially reducing rather than completely blocking venous blood flow is more similar to the process of venous thrombus in humans. Technically, this implies only partial ligation of side branches of the IVC and using a wire as a spacer during IVC ligation that, once removed, maintains a small lumen with a residual flow avoiding endothelial cell damage (15–21). These subtle modifications mimic a residual flow that is typical for human venous thrombosis and critical for its pathophysiology. As a disadvantage, the thrombus formed in the IVC is generally smaller and the size is more variable (22). This model allows us to better study early thrombotic events (16).

**Electrolytic Inferior Vena Cava Thrombosis Model**

Cooley et al. first described thrombus induction by electrical injury to the common femoral vein of mice (23, 24). Diaz et al. modified the protocol by applying a constant current to a copper wire inserted into the IVC. The electrical current induces free radicals inside the wire, which subsequently activate endothelial cells with minor cell damage (25–27). A thrombus develops quickly in the direction of the blood flow and thrombus sizes are highly consistent. This venous thrombosis model is used to study pro-thrombotic, anti-thrombotic, and thrombolytic therapies (28–30). Moreover, this model can mimic the early and late stages of venous thrombosis. Disadvantages include long procedure time and potential venous wall injury.

**Ferric Chloride (FeCl₃) Inferior Vena Cava Thrombosis Model**

Local application of FeCl₃ solution causes oxidative damage to the surface of the exposed venous wall followed by thrombus formation (31, 32). To achieve this, a small piece of filter paper soaked with a defined concentration of FeCl₃ solution is applied to the IVC for 3 min (33). As toxin exposure allows only a short observation period, thrombus size is usually small with little thrombus material for evaluation. Gustafsson et al. combined FeCl₃-induced vessel injury with IVC stenosis in rats to obtain a larger thrombus size (34).

**Recurrent Inferior Vena Cava Thrombosis Model**

Patients with deep vein thrombosis face a high risk of post-thrombotic syndrome and 30% experience recurrent thrombosis with 45% occurring in the ipsilateral leg within the following 10 years. Attempts to model recurrent thrombosis employ first the electrolytic method and 21 days later a secondary thrombus is induced using either a second electric insult or a ligature-based method. At the time of the second intervention, the primary thrombus has been incorporated into the venous wall, and the lumen has recovered. This clinically more relevant model has proven valuable to study the biology of recurrent deep vein thrombosis (35).

**Experimental Models of Arterial Thrombosis**

Arterial thrombosis is followed by territorial ischemia and infarcts during spontaneous rupture of atherosclerotic plaques, or in patients with an anti-phospholipid syndrome or with trauma. Arterial thrombosis is the central pathologic mechanism contributing to myocardial infarction and ischemic stroke (81). It is a major health concern in terms of cardiovascular morbidity
and mortality and has become an attractive drug target for the treatment of these diseases. A variety of reproducible animal models have been developed to investigate the pathomechanisms of arterial thrombosis (Table 1).

### Photothermotic Model of Cerebral Stroke

The photothermotic model uses a photosensitive dye (e.g., Rose Bengal) that after injection responds to illumination across the intact or thinned skull with laser light of a specific wavelength (36, 37). Light exposure induces the formation of oxygen and superoxide radicals damaging surrounding endothelial cell membranes. Endothelial damage promotes local activation and aggregation of platelets. As a consequence, platelet-rich thrombi occluding cerebral microvessels, and causing cortical ischemic infarcts. The photothermotic stroke model involves the neuroplasticity of perilesional and contralesional brain tissues (38, 39). Modifications of the classical photothermotic stroke model mimic also a perilesional penumbra. A ring filter model produces a central area of brain injury surrounded by tissue without thrombosis (40), but whether this model sufficiently reflects the penumbra in a human disease context is still under discussion (41). Other modifications include the targeting of individual brain arterioles or implantable optical fibers to produce small subcortical infarcts (42, 43), which surround areas of hypoperfusion with characteristics resembling an inverted penumbra (40). The photothermotic stroke model allows real-time analysis of many parameters in freely moving rats and mice with acute stroke without the need for anesthesia (44, 45). The activating light can be placed into the specific cortical region of the desired brain area. Using this in vivo model, highly reproducible infarct size and low mortality are suitable to study repair mechanisms of the brain and related long-term functional outcomes (46, 47). Since microvascular clots are unusually platelet-rich recombinant tissue plasminogen activator (t-PA) can resolve such clots to a limited extent (42).

### Table 1: Animal models of immunothrombosis

| Model                      | Strengths                                                                 | Weaknesses                                                                 | References |
|----------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|------------|
| Venous thrombosis          |                                                                           |                                                                           |            |
| IVC stenosis model         | Thrombus reduces blood flow, endothelial cell damage.                     | Thrombus formation is strain-dependent, clump relevant injury is unclear. | (16–22)    |
| Modified IVC stenosis model| Thrombus reduces blood flow, no endothelial cell damage.                  | Variable in thrombus incidence and size.                                  | (16–22)    |
| Electrolytic IVC model (EIM)| Thrombus size is highly consistent, with no endothelial cells damage.     | Long operation time.                                                      | (23–30)    |
| FeCl3 IVC model            | Produces thrombus within minutes, thrombus size is time-dependent.        | Transmural vein wall injury, the thrombus is small, only be used to study early time points. | (31–34)    |
| Recurrent IVC model        | Most clinically relevant.                                                 | Twice surgeries on the same mouse.                                        | (35)       |
| Arterial thrombosis        |                                                                           |                                                                           |            |
| Photothermotic model        | Localize the ischemic lesion, minimal variation in infarction, low mortality and invasiveness, highly reproducible. | The translational impact is poor.                                         | (36–47)    |
| Thromboembolic clot models  | Any kind of embolus-like material can be used, perfectly matches human embolic stroke. | High variability in infarct size, embolic material not lysable, high price. | (48–52)    |
| Microsphere/macrosphere model | Infarcts with penumbras, induce ischemic cell death and inflammation. Occlusion can be postponed. | Permanent ischemia, multiple vessels occluded, blood flow redistribution, immediate disruption of the blood-brain barrier and vasogenic edema. | (53–55)    |
| Cholesterol clot model     | Cholesterol crystal triggers clots formation, appropriate for thrombolytic agent study, low mortality, low invasiveness, highly reproducible. | Requires a high degree of surgical skill, the high variability of infarct size, localized ischemic region. | (56)       |
| Thrombotic microangiopathy |                                                                           |                                                                           |            |
| Acquired TTP model         | A simple approach leads to salient features of TTP                        |                                                                           | (57–61)    |
| Hereditary TTP model       | Spontaneous thrombocytopenia                                              |                                                                           | (61)       |
| HIT/T model                | Severe thrombocytopenia, allowing pre-clinical studies.                   |                                                                           | (62–65)    |
| Disseminated intravascular coagulation (DIC) |                                                                           |                                                                           |            |
| Sepsis-related DIC model   | Inducible DIC with multiple organ failure, suitable for candidate drugs testing. |                                                                           | (66–74)    |
| CLP-related DIC model      | Inducible DIC with multiple organ failure. Technically easy, reproducible and similar to human disease. |                                                                           | (75–79)    |

IVC, inferior vena cava; TTP, thrombotic thrombocytopenic purpura; HIT/T, heparin-induced thrombocytopenia/thrombosis; CLP, cecal ligation and puncture.
**Thromboembolic Stroke Model**

This model is frequently referred to study human thromboembolic stroke, injecting thrombus-like materials into the cerebral vessels, and the internal carotid artery (48, 49). Depending on the size and amount of the injected material, this model is characterized by leading to one or multiple arterial occlusions followed by ischemic infaracts in the respective territory. Compared to models of middle cerebral artery occlusion (MCAO), cerebral thromboembolism models-induced brain infaracts are surrounded by a well-defined penumbra but infarct sizes are more variable. This model is suitable to study the pathomechanisms of arterial immunothrombosis and the effects of thrombolytic drugs in this process (50, 51). However, the admitting source of the embolus is still not part of this model (52).

**Microsphere/Macrosphere Embolic Stroke Model**

Embolic stroke can also be induced by injection of synthetic large-sized macrospheres (diameter between 300 and 400 µm) or small-sized microspheres (diameter between 20 and 50 µm) into the cerebral artery. Many different materials, such as silicone, collagen, and titanium dioxide have been used to induce embolic stroke in vivo (53). This model has been characterized by permanent ischemia as the fibrinolytic system cannot dissolve such spheres. Microspheres cause multifocal and heterogeneous small infarcts due to microembolization into multiple arteries (54). Unlike thrombus formation, microspheres block blood vessels suddenly, leading to a rapidly developing edema and redistribution of blood flow (55). Although the macrosphere model induces similar infarct development to the ligation models, it does not allow to study the effect of thrombolytic drugs.

**Cholesterol Embolism Model**

We recently developed a model of cholesterol embolism by injecting cholesterol crystals into the left renal artery of mice (56). According to the size and number of cholesterol crystals, intrarterial injection leads to multiple microvascular thrombotic occlusions followed by ischemic territorial infaracts. Interestingly, these occlusions are sensitive to thrombolytic therapy preventing tissue infarction and kidney failure. However, it does not appear to be the crystals themselves but rather the blood clots surrounding the crystals that cause vascular obstruction, tissue ischemia, and organ failure (56). As a disadvantage, infarct size is highly variable in this model but the degree of organ failure tightly correlates with the injected crystal dose.

**Experimental Models of Thrombotic Microangiopathy**

Thrombotic microangiopathies (TMAs) are heterogeneous disorders characterized by thrombocytopenia, microangiopathic hemolytic anemia, renal failure, and neurological symptoms (82). Complex histopathological features have been detected in TMAs, including thrombosis in arterioles and capillaries with abnormalities in the endothelium and vessel wall [Table 1; (83)]. TMAs can result from having numerous different pathophysiological mechanisms resulting in a spectrum of distinct but frequently overlapping clinical presentations, as discussed in detail elsewhere (84). An important element is genetic and acquired complement system alterations that either alone or in combination with other triggers cause TMA. Such triggers of uncontrolled complement activation at the endothelial interface include infections, bacterial toxins, certain drugs, and malignancies. Placental as well as maternal factors can trigger TMA during pregnancy that can present with different clinical features referred to by a traditional nomenclature, i.e., (pre-) eclampsia or hemolysis-elevated liver enzymes and low platelet count (HELLP) syndrome. Another entity relates to the von Willebrand factor (vWF) cleaving protease disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13)-induced damages. Given this complexity of disease pathomechanisms, animal models of TMA can mimic only selective scenarios of the broad clinical spectrum of TMA. Some are presented here.

**Thrombotic Thrombocytopenic Purpura (TTP) Models**

TTP develops from absence or inactivation of the ADAMTS13, leading to the accumulation of vWF multimers and the formation of microvascular thrombi with ischemic end-organ damage (57, 82). Two important mouse models have been developed to study the ADAMTS13 function in vivo. The TTP-ADAMTS13 proteolytic activity inhibition model is based on the administration of human anti-ADAMTS13 recombinant single-chain variable region antibody fragments (scFv’s), which inhibits the enzymatic activity of ADAMTS13 in mice (58, 59). This in vivo treatment leads to persisted ADAMTS13 deficiency for over 2 weeks and the formation of microvascular thrombi (58, 60). Administration of Shiga toxin-2 to these mice results in lethal TMA affecting the brain, heart, and kidney (61). In another mouse model, ADAMTS13-deficient mice are challenged with a second hit to develop TTP, e.g., the infusion of Shiga toxin causes a syndrome closely resembling human TTP with widespread vWF-rich and fibrin-poor hyaline thrombi in the microvasculature of multiple organs (62).

**Heparin-Induced Thrombocytopenia (HIT) and Thrombosis**

Heparin can trigger an immune-mediated thrombocytopenic disorder characterized by venous and arterial thrombus formation via antibodies against complexes of human platelet factor 4 (PF4) and heparin (63, 64). Heparin-induced thrombocytopenia in mice requires transgenic expression of human PF4 and a lack of the genetic equivalent of human Fc gamma receptor IIA (FcrIIIA). As a third requirement, mice are injected with anti-heparin-PF4 immunoglobulin (IgG) and heparin (64, 65, 85). Although this combination of causal factors is not identical to the clinical scenario in patients, the mouse model is suitable to study HIT. Also, in some cases, lethal TTP with disseminated arterial and venous thrombi have been described in mouse models of HIT.

**Disseminated Intravascular Coagulation (DIC) Model**

Thrombocytopenia is frequently observed in septic patients who have a systemic activation of immunothrombotic mechanisms (66, 86, 87). Several important models have been developed to study the pathology of DIC in mice. In the endotoxemia model,
injection of lipopolysaccharide (LPS), zymosan or E. coli bacteria in mice initiates an overwhelming activation of innate immunity and procoagulant pathways that can lead to DIC with multiple organ dysfunction (67–70). Pathophysiological characteristics of this treatment are reduced platelet count, prolonged bleeding time, decreased plasma fibrinogen levels, and increased plasma D-dimer levels (71–73). This model is often used for the testing of drug candidates (74, 75).

Caecal Ligation and Puncture Model
This represents the gold standard for research on polymicrobial sepsis (76, 77). It consists of DIC-like microvascular thrombosis and multiple organ failure representing an irreversible stage of sepsis (78, 79).

Cellular Components and Molecular Mechanisms of Immunothrombosis
Platelets
Studies using mouse models of sepsis revealed the accumulation of platelets in the microvasculature. Indeed, LPS injection resulted in thrombocytopenia in mice, the accumulation of platelets was found in the lung and liver. Several Toll-like receptors (TLRs) were identified in human and mouse platelets to bind a major component of the wall of gram-negative microorganisms (LPS), transmitting signals between platelets and the innate immune system, thereby inducing inflammatory responses. TLR-2 and -4 on human and mouse platelets bind LPS and increase nitric oxide and cyclic guanosine monophosphate (GMP) levels, and activate protein kinase G (88). TLR4 activates the nuclear factor-κB (NF-κB) and the mitogen-activated protein (MAP) kinases increasing interleukin6 (IL-6), cyclooxygenase (COX-2), and prostaglandin E2 (PGE2) production (89). Platelet TLR-1- and -4 are involved in the development of microvascular thrombosis and sepsis-induced intravascular coagulation by triggering platelet degranulation, which releases proinflammatory cytokines from alpha (α)-granules and promotes platelet-neutrophil interaction (Figure 1). Several other isoforms of TLRs have been studied in human and mouse platelets, connecting TLR signaling to pathogenesis of virus-induced thrombocytopenia, and intravascular coagulation. Platelet glycoprotein (GP) Ib and αIIBβ3 integrins are involved in this process, together with an extracellular matrix bridge formed by vWF and fibrinogen. It has been shown that collagen-mediated-activation of GPVI signaling in platelets plays an important role in platelet adhesion onto the inflamed endothelium (90). Altogether, these results suggest that platelets can distinguish between cellular immunity and hemostasis using a combination of different platelet TLRs and, depending on the ligand binding of the pathogens, platelet TLRs can transduce effector signals to immune cells.

Endothelial Injury, TF, and Thrombus Formation
In the inflamed vessel wall, endothelial cells start to expose TF and extracellular matrix molecules at the luminal surface, which induces functional crosstalk between platelets, immune cells and activates the coagulation cascade. Platelets and neutrophils are the first blood cells adhering to the luminal endothelial surface of the inflamed vessel wall. Platelet GPIb binds vWF, GPVI binds collagen, laminin, and fibrin (91, 92). Besides these interactions, α2β1 integrin and GPV bind collagen, and α6β1 interacts with laminin during thrombus formation (93, 94). Thrombus growth involves additional platelet recruitment, thereby accelerating the coagulation cascade and the immune response, which stabilizes the growing thrombus on the endothelial surface (Figure 1). Thrombin generation amplifies platelet granule secretion priming the innate immune system. Granule-resident factors released by platelets have diverse effects on the innate immune system, including monocyte cell differentiation (95), neutrophil cell migration (96), phagocytosis, and cytokine responses. For example, platelet granules contain second wave mediators [adenosine triphosphate (ATP) and serotonin], plasma factors, TFs, fibrinogen, and (pro-)inflammatory cytokines, and chemokines. Platelet serotonin released from delta (δ)-granules could significantly increase neutrophil accumulation and extravasation during inflammation (97). Platelet inflammatory cytokines interleukin-1 (IL-1), regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES), platelet-derived growth factor (PDGF), transforming growth factor-β (TGFβ), and epidermal growth factor (EGF) enhance local inflammatory responses and supported by platelet chemokines, such as chemokine (C-C motif) ligand 5 (CCL5), chemokine (C-X-C motif) ligand 4 (CXCL4), and 7 (CXCL7) that activate monocytes and neutrophils. Interestingly, monocytes express TF in certain pathological conditions (98, 99), connecting the innate immune system to the coagulation cascade. In addition, microparticles released by monocytes bind the platelet surface to accumulate TFs and to promote coagulation (100).

Platelet-Immune Cell Interactions
Platelet attachment to the inflamed vessel walls is supported by the interaction between platelets and extracellular matrix components, thereby promoting the interaction of platelets with immune cells and endothelial cells. Indeed, the interaction of surface receptors of activated immune cells and platelets strongly influences innate immune responses. It has been shown that liver-resident macrophages (Kupffer cells) can interact with platelets via platelet GPIb receptor and the exposed vWF on the Kupffer cell surface, e.g., during bacterial infection-induced immunothrombosis (101). Such platelet-immune cell conjugates correlate to the severity of sepsis (102). Although the detected lifetime of this conjugates in the peripheral blood is very short, this interaction activates integrins and induces granule secretion. Platelet-neutrophil adhesion to the endothelium involves the interaction between neutrophil P-selectin glycoprotein ligand-1 (PSGL-1) and αMβ2 integrin to platelet P-selectin and GPIb, respectively. Neutrophil macrophage antigen 1 (Mac-1) also binds platelet GPIb and αIIBβ3 integrin in the presence of fibrinogen, inducing exposure of proinflammatory chemokines CXCL4 and CCL5 (103). P-selectin and PSGL-1 interactions also contribute to the formation of platelet-monocyte conjugates resulting in monocyte activation. Also, monocyte-resident Mac-1 receptor and platelet adhesion receptors GPIb, junction
adhesion molecule 3 (JAM3), or αIIbβ3 integrin form transient interactions (104).

Platelets and NET Formation
Electron micrographs showed adhesion and aggregation of activated platelet within a fibrous meshwork of NETs (105). In addition, platelet aggregation occurred in a time-dependent manner, and DNase treatment simultaneously cleared NETs and platelets (105). The release of NET into the circulation is followed by platelet adhesion and aggregation, which together with histones released from NETs promote thrombus formation and growth (4). The NET release was observed also in non-infectious inflammatory conditions, such as venous-, microvascular-, and cancer-related thrombosis, acute lung injury, endothelial damage with trauma, autoimmune diseases, preeclampsia, and systemic lupus erythematosus (106). Interestingly, the structure of thrombi in the presence of NETs is more rigid and less permeable. In a mouse model of sepsis, TLR2, and TLR4 on the surface of platelets in liver sinusoids and lung capillaries contribute to platelet-neutrophil interaction and NET formation (107). In addition, synchronized activation of surface integrins and chemokine receptors induce NET formation (108). Thromboxane A2 (TxA2)-released from activated platelets can also amplify NET formation and this process is inhibited by aspirin (109).

Coagulation
The blood coagulation cascade operates in three steps: (i) formation of prothrombin activator, (ii) conversion of prothrombin to thrombin, and (iii) conversion of fibrinogen to fibrin (Figure 1). The first step involves the intrinsic coagulation pathways. The intrinsic pathway is activated by exposure of endothelial collagen and the extrinsic pathway is activated through TF released by injured endothelial cells. The following two steps encase platelet aggregates and red blood cells into a fibrin network and attach it to the damaged endothelium. At sites of the damaged vessel wall, platelet activation and degranulation convert inactive IL-1 to the active form by thrombin cleavage, thereby connecting the coagulation system to immunothrombosis. NET release influences the coagulation cascade by activating coagulation factor XII (FXII), inactivating anticoagulant tissue factor pathway inhibitor (TFPI), and by providing an active surface for platelet adhesion and aggregation. All of these mechanisms lead to the inhibition of fibrinolytic activity, thereby promoting thrombus formation and growth.
Several experimental studies confirmed the presence of extracellular DNA in venous thrombi induced by the restriction of blood flow (16, 114, 115). In a mouse model of acute limb ischemia-reperfusion injury, DNase I treatment significantly reduced the presence of extracellular DNA traps, immune cell infiltration, thrombin-anti-thrombin-III generation, and enhanced post-ischemic hind limb perfusion. Interestingly, neutrophil depletion resulted only in a small reduction in DNA traps without inducing any skeletal muscle injury, or hind limb perfusion (116). Indeed, ex vivo experiments showed that DNA-histone complexes stabilized the fibrin network resulting in a higher rigidity of an artificial thrombus that was resistant to t-PA. In contrast, adding DNase I promoted clot lysis in combination with t-PA (117). Thus, evolving data in a set of different models of venous thrombosis consistently demonstrated a role of extracellular DNA in venous thrombosis.

**Contribution of Extracellular DNA to Arterial Thrombosis**

Numerous studies on animal models suggested the role of extracellular DNA in arterial thrombosis. In murine models of atherosclerosis, DNase I treatment resulted in a reduced burden of atherosclerosis (118). Recently, we showed that in a murine model of cholesterol embolism, extracellular DNA can be a non-redundant component of crystal clots forming within a few hours upon embolization and vascular occlusion. Similar to the platelet purinergic receptor P2Y12 antagonism with clopidogrel, DNase I treatment significantly reduced the numbers of obstructed arteries, decreased ischemic-related organ failure, and tissue infarction (56). In addition, preincubation of washed platelets with DNase I inhibited platelet activation, P-selectin exposure, thrombus formation, and inflammation, and suppressed organ damage.

**Pro-Thrombotic Danger-Associated Molecular Patterns (DAMPs): The Role of Extracellular DNA in Immunothrombosis**

Among the mediators released from injured cells, extracellular DNA acts as pro-thrombotic DAMP (110–112). Released chromatin forms similar functional structures as the fibrin network to trap red blood cells, platelets, and coagulation factors including TF and fibrin (113). Here, we discuss some experimental pieces of evidence derived from studies on venous, arterial and microvascular thrombosis, and ischemic stroke (Table 2).

### Contribution of Extracellular DNA to Venous Thrombosis

Several animal models established the role of extracellular DNA in venous thrombosis (Table 2). Ligation of the IVC in mice can increase plasma levels of extracellular DNA during several days (114). Immunofluorescence studies revealed colocalization of extracellular DNA with histones and vWF in the thrombus. DNase I administration protected mice from thrombosis at 6 h and 48 h in this model, indicating that the extracellular DNA itself is a critical component of fibrin-rich thrombi. Several experimental studies confirmed the presence of extracellular DNA in venous thrombi induced by the restriction of blood flow (16, 114, 115).
and aggregation response to a collagen-related peptide (CRP) and thrombin. Furthermore, treatment with DNase I inhibits ATP release and the formation of a fibrin network.

**Contribution of Extracellular DNA in Ischemic Stroke**

In stroke patients, extracellular DNA components have been also observed in ischemic brain tissues, possibly contributing to stroke development. In support of this, histological analysis of thrombi collected from stroke patients revealed that a large number of nucleated leukocytes presented in all thrombosis specimens, neutrophils were abundant in all observed thrombi, and NETs were found in all thrombi, in particular in their outer layers (119, 120). In a murine model of transient middle cerebral artery occlusion (tMCAO), increased levels of circulating nucleosomes and DNA were found after ischemic stroke. Under hypoxic conditions, an increased level of extracellular chromatin was detected. Moreover, targeting extracellular chromatin components with DNase I improved stroke outcome (121). Strikingly, adding DNase I to t-PA significantly accelerated the ex vivo lysis of thrombi compared to t-PA alone (119, 120).

**Contribution of Extracellular DNA to Thrombus Formation in the Microvasculature**

Recent experimental evidence suggests that extracellular DNA plays an important role in DIC-related organ dysfunction, probably caused by elevated levels of circulating thrombin, high platelet aggregation, vascular leakage, the release of proinflammatory cytokines, and NET formation (128). In sepsis-induced DIC, large numbers of NETs are accumulated mainly in the microvasculature of the lung and liver (124). Studies using DNase-deficient mice reported that the formation of NET clots associates with TMA and DIC, including schistocytes, hemolytic anemia, and organ failure due to vascular occlusions. Similar observations have been detected in patients with severe bacterial infections (124). Studies using multicolor confocal intravital microscopy showed the presence of aggregated platelets and fibrin clots together with extracellular DNA in septic tissues (125). NETosis is regulated by the citrullinating enzyme peptidyl arginine deiminase 4 (PAD4) which induces decondensation of the chromatin through arginine modification of histones. Accordingly, in mouse models of sepsis, deficiency of PAD4, or DNase I treatment significantly inhibited systemic intravascular thrombin activity, reduced platelet aggregation, and improved microvascular perfusion (125). Patients with acute TMA show lower plasma levels of DNase I when compared with healthy controls (127). In a murine caecal ligation and puncture model, a time-dependent increase in cell-free DNA was accompanied by systemic inflammation (126). Interestingly, early administration of DNase I at 2 h after caecal ligation and puncture resulted in a drop in circulating cell-free DNA levels, increased inflammation, and organ damage in the lungs and kidneys. In contrast, later administration of DNase I, 4 or 6 h after caecal ligation and puncture, resulted in less cell-free DNA and inflammation, preventing organ damage and improving survival (126).

In a mouse model of HIT, thrombi are composed of neutrophils, extracellular DNA, citrullinated histone H3, and platelets. Interestingly, neutrophil depletion or Pad4-deficiency abrogates thrombus formation and DNase I treatment reduced the size of venous thrombi (122, 123).

As the studies on animal models supported a therapeutic potential of recombinant DNase I against thrombus formation in different types of vessels, this concept deserves further investigation at the clinical level. Recently, clinical studies suggested that endogenous DNase I activity could represent a therapeutic biomarker during acute myocardial infarction (129). Accordingly, coronary NET burden and endogenous DNase activity are shown as predictors of myocardial infarct size and stenosis resolution (130). Indeed, recombinant DNase I can accelerate t-PA-mediated lysis of human coronary and cerebral thrombi ex vivo (119, 120). Patients with acute microvascular thrombosis displayed reduced DNase I activity (127). Timely and efficient removal of extracellular DNA is required to prevent excessive thrombus formation. The restoration of plasma DNase I activity possibly represents a new therapy for thrombotic complications.

**Cellular Sources of Extracellular DNA in Immunothrombosis**

Extracellular DNA could be released by activated immune cells such as neutrophils and monocytes, by apoptotic platelets or by the damaged vasculature (131–134). Therefore, it is difficult to identify precisely the sources of extracellular DNA that contribute to thrombus formation in vivo context. Neutrophils are considered as a major source of extracellular DNA when they release their chromatin as NETs (105, 135). As indicated above, NETs are critical for the development of sepsis-induced intravascular coagulation regardless of the inciting bacterial stimulus (gram-negative, gram-positive, or bacterial products). Indeed, many clinical and experimental studies use extracellular DNA as a marker for NETs in the circulation. NETs and extracellular DNA are present in patients with HIT. In patients with myocardial infarction, blood samples contain DNA, nucleosomes, myeloperoxidase, and neutrophil elastase, and their plasma levels correlated with the burden of NETs, detected within coronary thrombi, as well as with the infarct size (130). In ischemic stroke, thrombi in cerebral arteries stain positive for neutrophils, extracellular DNA, and neutrophil elastase, suggesting NET formation (119).

Extracellular traps are also released from monocytes, referred to as METs. METs have a similar web-like structure comprising DNA, granular enzymes, and citrullinated histones, and procoagulant activity, similar to NETs (132). Besides neutrophils and monocytes, it has been reported that eosinophils also form extracellular traps (134).

Another source of extracellular DNA can be released by necrotic vascular or parenchymal cells. During thrombosis-induced tissue ischemia, the majority of cells die primarily via a process of necrosis, this process releases nuclear DNA into the extracellular space and bloodstream. Injured cardiomyocytes are probably a major source of extracellular DNA in patients.
with myocardial infarction (136, 137). Another source is injured endothelial cells at the site of vascular obstruction (56, 138). Finally, activated platelets release DNA from their mitochondria. Although the total amount of mitochondrial DNA per platelet is low, the large numbers of platelets involved in blood clotting also render platelets as a potentially significant source of extracellular DNA (139, 140). Taken together, numerous sources contribute to the pool of extracellular DNA in immunothrombosis.

**Therapeutic Potential of Recombinant DNase I in Immunothrombosis**

In a mouse model of sepsis-induced intravascular coagulation, NET release coincided with increased platelet aggregation, thrombin generation, and fibrin clot formation (125). DNase I treatment reduced NET formation and degraded extracellular DNA, which was associated with inhibited platelet aggregation and microvascular obstructions (Figure 2). In the LPS-induced sepsis mouse model, NET release and fibrin clot formation were inhibited by the combined treatment of DNase I with the thrombin inhibitor argatroban. However, these treatments did not influence bacterial dissemination (141). In line with this, in septic patients, NETs also significantly increased the generation of thrombin and fibrin clot formation, and this effect was reduced by DNase I treatment (142). Of note, DNase I treatment leads to the release of NET components into the bloodstream, which may elicit procoagulant activity and intravascular thrombosis in septic patients. Free extracellular DNA fragments enhance the intrinsic coagulation pathway (143), which is also observed in patients with deep vein thrombosis (144), leading to tissue hypoxia and endothelial damage.

It is known that DNA intercalates with fibrin to form a scaffold that stabilizes clot structure in the bloodstream (4), therefore DNA-fibrin complexes have a fundamental effect on clot lysis. In plasma of septic patients, extracellular DNA significantly delayed t-PA-mediated clot lysis times by forming DNA-plasmin-fibrin ternary complex which results in a densely packed clot structure (145). Elevated levels of extracellular DNA in plasma from septic patients promoted thrombin generation (146). DNA alone or NETs inhibited plasminogen activation and t-PA-induced resolution of plasma clots (147). In a murine model of HIT, PF4 combines with NET-forming complexes that selectively bind HIT-induced antibodies, DNAse I treatment limited venous thrombus size (148). Extracellular DNA markedly affects the hemostatic system by activating factor XI (FXI) and factor XII (FXII) (149). Extracellular DNA present in the fibrin clot inhibits the antithrombotic activities of anticoagulants, such as unfractionated heparin and enoxaparin (150). In contrast, RE31 DNA aptamers inhibit thrombin formation, accelerates fibrinolysis in vitro, and suppress thrombosis in vivo (151, 152).

In cystic fibrosis the lung is frequently affected by recurrent bacterial infections and chronic inflammation causing progressive lung destruction; the development of thick mucus in small bronchioles and peribronchial regions of the lung thereby triggering permanent bacterial infection. Infiltrated neutrophils release granular content to eliminate the pathogens, and also release high concentrations of extracellular DNA, forming NETs in the inflamed bronchioles, which contribute to airway damage, aggravating mucus viscosity, and its mucociliary clearance from the bronchioles. Blood samples from patients with cystic fibrosis showed an increased number of activated platelets (153), which form cell conjugates with monocytes and neutrophils (153, 154). Increased platelet aggregation responses to adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP), and second-wave mediators (TXA2, ATP, serotonin), and α-granule-resident proteins [tumor necrosis factor alpha (TNFα), CD40 ligand (CD40L), leukotriene B4 (LTB4), and interleukins] were also detected (155, 156). Plasma levels of platelet granule-resident proteins are correlated with a decreased lung function of these patients (157, 158). DNase I treatment showed significant improvement in rheological parameters in cystic fibrosis, reducing the thick mucus layer by cleaving the extracellular DNA of NETs. Therefore, patients can release more easily the accumulated mucus up from the inflamed lung tissue.

The literature also describes that following bacteremia, neutrophils recruited to the liver sinusoids enhance the clearance of pathogens from the circulation (107, 159). Similar to the phenomenon observed in septic lung tissues, and in liver sinusoids, neutrophils also release intravascular NETs (69). Blocking NET formation by DNase I reduced the capture of circulating bacteria in the liver, resulting in decreased dissemination of bacteria to distant organs.

NET formation was also detected in acute ischemic stroke, located in the outer layer of developing thrombi, and consequently, the increase of extracellular DNA content in the blood plasma correlates with stroke severity. Although thrombolysis with t-PA administration promotes fibrin degradation in the occluded vessel of acute ischemic stroke, t-PA-resistant clot formation has been frequently observed in platelet-rich arterial thrombi. Hence, fibrin accumulation in the growing thrombi is limited at the early phase of acute ischemic stroke (160, 161). Interestingly, the co-administration of DNase I with t-PA accelerated thrombolysis ex vivo. However, DNase I treatment alone had no thrombolytic effect ex vivo. These results suggest that both fibrin and NET formations can be targeted simultaneously to induce successful thrombolysis and recanalization of the artery in acute ischemic stroke (120). In line with these results, combined treatment of DNase I with t-PA also attenuated infarct size in a murine model of myocardial ischemia-reperfusion injury. Again, DNase I or t-PA treatment alone had no beneficial effects in this mouse model (162). Altogether, these results suggest that DNase I and t-PA treatment together improve both myocardial and cerebral post-ischemic infarction. However, a clinically implemented and safe pharmacological strategy of DNase I treatment is currently established in patients with cystic fibrosis (163) and limited clinical trials investigated the thrombolytic effects of NET degradation in other disease conditions. Altogether, these data suggest that in some cases, DNA-targeted therapies by DNase I may improve thrombolysis and inhibit coagulation. Therefore, further investigation is necessary to establish the role of DNase I treatment in immunothrombosis.
CONCLUSIONS AND FUTURE PERSPECTIVES

Immunothrombosis is a complex process involving numerous elements of the cascades of coagulation and inflammation. In vivo preemptive administration of recombinant DNase I not only cleaves deposits of extracellular DNA but also inhibits ATP release from platelet δ-granules and prevents the formation of fibrin network. Extracellular DNA may directly induce fibrin formation, thereby enhancing thrombus growth. Studies
analyzing the role of extracellular DNA in immunothrombosis related to either the use of DNase-deficient mice or the recombinant DNase I. It is worth to postulate that DNase I treatment may limit thrombus formation by inhibiting the function of platelet-derived second wave mediators, such as ATP.

Several questions remain unanswered: What is the main source of extracellular DNA during the early phase of blood clotting in vivo? How does the extracellular DNA released from infarcted tissues may contribute to the clot formation and the resistance to the fibrinolysis? Is extracellular DNA a suitable therapeutic target in humans beyond the anticoagulants or fibrinolytic drugs? Does recombinant DNase I have a better safety profile compared to the anticoagulants? A better understanding of the role of extracellular DNA in a immunothrombosis context is required to clarify these issues.

**REFERENCES**

1. Hagemann JH, Haegle H, Muller S, Anders H-J. Danger control programs cause tissue injury and remodeling. Int J Mol Sci. (2013) 14:11319–46. doi: 10.3390/ijms140611319
2. Lei Y, Anders H-J. Evolutionary trade-offs in kidney injury and repair. Histol Histopathol. (2017) 32:1099–113. doi: 10.14670/HH-11-900
3. Engelmel B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. (2013) 13:34–45. doi: 10.1038/nri3345
4. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DDJ, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. (2010) 107:15880–5. doi: 10.1073/pnas.1005743107
5. Herwald H, Egesten A. On PAMPs and DAMPs. J Innate Immun. (2016) 8:427–8. doi: 10.1159/000448437
6. Linkermann A, Stockwell BR, Krautwald S, Anders H-J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol. (2014) 14:759–75. doi: 10.1038/nri3743
7. Sarhan M, Land WG, Tonnus W, Hugo CP, Linkermann A. Origin and consequences of necroinflammation. Physiol Rev. (2018) 98:727–80. doi: 10.1152/physrev.0041.2016
8. Cooley BC. Murine models of thrombosis. Thromb Res. (2012) 129(Suppl.1):S62–4. doi: 10.1016/j.thromres.2012.02.036
9. Zhou J, May L, Liao P, Gross PL, Weitz JI. Inferior vena cava ligature rapidly induces tissue factor expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol. (2009) 29:863–9. doi: 10.1161/ATVBAHA.109.185678
10. Patterson KA, Zhang X, Wrobleski SK, Hawley AE, Lawrence DA, Wakefield TW, et al. Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res. (2013) 131:268–76. doi: 10.1016/j.thromres.2012.12.006
11. Nakazawa D, Desai J, Steiger S, Muller S, Devarapu SK, Mulay SR, et al. Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombi. Cell Death Discov. (2018) 5:6. doi: 10.1038/s41420-018-0073-2
12. Henke PK, Mitsuya M, Luke CE, Elliff MA, Baldwin JF, Deatrick KB, et al. Toll-like receptor 9 signaling is critical for early experimental deep vein thrombosis resolution. Arterioscler Thromb Vasc Biol. (2011) 31:43–9. doi: 10.1161/ATVBAHA.110.216317
13. Deatrick KB, Luke CE, Elliff MA, Sood V, Baldwin JI, Upchurch GRJ, et al. The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling. J Vasc Surg. (2013) 58:1375–84.e2. doi: 10.1016/j.jvs.2012.11.088
14. Peteren L, Drevensek G, Cerne M, Stalc A, Stegnar M, Buddhism M, V. Evaluation of two experimental venous thrombosis models in the rat. Thromb Res. (2005) 115:527–34. doi: 10.1016/j.thromres.2004.10.007
15. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Kollinberger M, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. (2011) 117:1400–7. doi: 10.1182/blood-2010-05-287623
16. von Bruhl M-L, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. (2012) 209:819–35. doi: 10.1084/jem.20112322
17. Payne H, Ponomaryov T, Watson SP, Brill A. Mouse with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood. (2017) 129:2013–20. doi: 10.1182/blood-2016-09-742999
18. Brill A, Yesilaltay A, De Meyer SF, Kisuucka J, Fuchs TA, Kocher O, et al. Extraheparin high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. Arterioscler Thromb Vasc Biol. (2012) 32:1841–7. doi: 10.1161/ATVBAHA.112.252130
19. Ponomaryov T, Payne H, Fabritz I, Wagner DD, Brill A. Mast cells granular contents are crucial for deep vein thrombosis in mice. Circ Res. (2017) 121:941–30. doi: 10.1161/CIRCRESAHA.117.311185
20. Aleman MM, Byrnes JR, Wang J-G, Tran R, Lam WA, Da Paola J, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. (2014) 124:3590–600. doi: 10.1172/JCI75386
21. Brandt M, Schonfelder T, Schwenk M, Becker C, Jackel S, Reinhardt C, et al. Deep vein thrombus formation induced by flow reduction in mice is determined by venous side branches. Clin Hemorheol Microcirc. (2014) 56:145–52. doi: 10.3233/CH-131680
22. Thomas GM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost. (2015) 13:1316–9. doi: 10.1111/jth.13002
23. Cooley BC, Szema L, Chen C-Y, Schwab JP, Schmeling G. A murine model of deep vein thrombosis: characterization and validation in transgenic mice. Thromb Haemost. (2005) 94:498–503. doi: 10.1160/TH05-03-0170
24. Cooley BC, Schmeling G. Murine model of large-vein electrolytic injury induction of thrombosis with slow resolution. Thromb Res. (2016) 140:149–52. doi: 10.1016/j.thromres.2016.01.023
25. Diaz JA, Alvarado CM, Wrobleski SK, Slack DW, Hawley AE, Farris DM, et al. The electrolytic inferior vena cava model (EIM) to study thrombogenesis and thrombus resolution with continuous blood flow in the mouse. Thromb Haemost. (2013) 109:1158–69. doi: 10.1160/TH12-09-0711
26. Diaz JA, Hawley AE, Alvarado CM, Berguer AM, Baker NK, Wrobleski SK, et al. Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model. Thromb Haemost. (2010) 104:366–75. doi: 10.1160/TH09-09-0672
27. Diaz JA, Wrobleski SK, Hawley AE, Lucchesi BR, Wakefield TW, Myers DDJ. Electrolytic inferior vena cava model (EIM) of venous thrombosis. J Vis Exp. (2011) 53:2737. doi: 10.3791/2737
28. Banno F, Kita T, Fernandez JA, Yamamoto H, Tashima Y, Kojame K, et al. Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. Blood. (2015) 126:2247–53. doi: 10.1182/blood-2015-06-653162

**AUTHOR CONTRIBUTIONS**

CS, H-JA, and AB wrote the manuscript and prepared tables. LY and CS prepared the figures. H-JA and AB revised the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the Deutsche Forschungsgemeinschaft (AN372/16-2, 20-2, 24-1) to H-JA and 374031971-TRR 240/A09 to AB. CS and LY were recipients of a stipendium from the Chinese Scholarship Council.
29. Diaz JA. Animal models of VT: to change or not to change? Blood. (2015) 126:2177–8. doi: 10.1182/blood-2015-08-664011
30. Palmer OR, Shyadakov ME, Rainey JP, Lawrence DA, Greve JM, Diaz JA. Update on the electrolytic IVC model for pre-clinical studies of venous thrombosis. Res Pract Thromb Haemost. (2018) 2:266–73. doi: 10.1093/rpth/cxy128
31. Jaffer FA, Tung C-H, Gersten RE, Weisleder R. In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arterioscler Thromb Vasc Biol. (2002) 22:1929–35. doi: 10.1161/01.ATV.0000038956.79070.DC
32. Jaffer FA, Tung C-H, Wykryzkowska JJ, Ho N-H, Houng AK, Reed GL, et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation. (2004) 110:170–6. doi: 10.1161/01.CIR.0000134484.11052.44
33. Wang X, Smith PL, Hsu M-Y, Ogletree ML, Schumacher WA. Marine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost. (2006) 4:403–10. doi: 10.1111/j.1538-7836.2006.00173.x
34. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gynander E, et al. The direct thrombin inhibitor melagatran and its oral produg H 379/59: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. (2001) 101:171–8. doi: 10.1016/S0049-3848(00)00399-6
35. Andraska EA, Luke CE, Elliffe MA, Henke SP, Madapoosi SS, Metz AK, et al. Pre-Clinical model to study recurrent venous thrombosis in the inferior vena cava. Thromb Haemost. (2018) 118:1048–57. doi: 10.1055/s-0038-1645855
36. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD. Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann Neurol. (1985) 17:497–504. doi: 10.1002/ana.10170513
37. Dietrich WD, Watson BD, Busto R, Ginsberg MD, Betha JR. Photochemically induced cerebral infarction. I. Early microvascular alterations. Acta Neuropathol. (1987) 72:315–25. doi: 10.1007/BF00687622
38. Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing movement therapy either in concurrent or in sequential combination with G-CSF treatment combined with concomitant or sequential treatment and G-CSF treatment combined with concomitant or sequential treatment. J Neurosci Methods. (2005) 145:123–8. doi: 10.1016/j.jneumeth.2004.04.002
39. Mayzel-Oreg O, Orly D, Kazemi M, Li F, Fisher M, Cohen Y, et al. Microsphere-induced embolic stroke: an MRI study. Magen Reson Med. (2004) 51:1233–40. doi: 10.1002/mrm.20109
40. Miyake K, Takeo S, Kajihara H. Sustained decrease in brain regional blood flow after microsphere embolism in rats. Stroke. (1993) 24:415–20. doi: 10.1161/01.STR.24.3.415
41. Shi C, Kim T, Steiger S, Mulay SR, Klinkhammer BM, Bauerle T, et al. Crystal clots as therapeutic target in cholesterol crystal embolism. Circ Res. (2020) 126:37–52. doi: 10.1161/CIRCRESAHA.119.315625
42. Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Progr. (2018) 2018:539–47. doi: 10.1182/ashedducation-2018.1.539
43. Osterparg EM, Beier K, Kacir S, Thiboutot M, Gulendran G, Yunk L, et al. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. Transfusion. (2016) 56:1775–85. doi: 10.1111/trf.13583
44. Neyman M, Gewertz J, Poncz M. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots. Blood. (2008) 112:1101–8. doi: 10.1182/blood-2008-04-152959
45. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. (1999) 6:1258–66. doi: 10.1038/sj.gt.3300991
46. Jin S-Y, Xiao J, Bao J, Zhou S, Wright JF, Zheng XL. AAV-mediated gene transfer in genetically susceptible ADAMTS13-deficient mice. J Neurosci. (2011) 31:851–60. doi: 10.1523/JNEUROSCI.0580-10.2011
47. Lu H, Li Y, Yuan L, Li H, Lu X, Tong S. Induction and imaging of photothrombotic stroke in conscious and freely moving rats. J Biomed Opt. (2019) 14:96013. doi: 10.1117/1.JBO.19.9.096013
48. Yu C-L, Zhou H, Chai A-P, Yang Y-X, Mao R-R, Xu L. Whole-body scale neurobehavioral assessments of photothrombotic ischemia in freely moving mice. J Neurosci Methods. (2015) 239:100–107. doi: 10.1016/j.jneumeth.2014.10.004
49. Diederich K, Quennet V, Bauer H, Muller HD, Wersching H, Schabitz W-R, et al. Successful regeneration after experimental stroke by granulocyte-colony stimulating factor is not further enhanced by constraint-induced movement therapy either in concurrent or in sequential combination with G-CSF treatment combined with concomitant or sequential...
67. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. (2010) 38:526–34. doi: 10.1097/CCM.0b013e318198d21

68. Dixon B. The role of microvascular thrombosis in sepsis. Anaesth Intensive Care. (2004) 32:619–29. doi: 10.1177/130500080403200502

69. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe. (2012) 12:324–33. doi: 10.1016/j.chom.2012.06.011

70. Yipp BG, Petri B, Salina D, Jenne CN, Scott BN V, Zbytnuk LD, et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat Med. (2012) 18:1386–93. doi: 10.1038/nm.2847

71. Cohen J. The immunopathogenesis of sepsis. Nature. (2002) 420:885–91. doi: 10.1038/nature01326

72. Riedemann NC, Guo R-F, Ward PA. The enigma of sepsis. J Clin Invest. (2003) 112:460–7. doi: 10.1172/JCI13019523

73. Berthselen LO, Kristensen AT, Tranholm M. Animal models of DIC and their relevance to human DIC: a systematic review. Thromb Res. (2011) 128:103–16. doi: 10.1016/j.thromres.2010.12.002

74. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res. (1990) 49:186–96. doi: 10.1006/jsre.1990.1026

75. Ayala A, Song GY, Chung CS, Redmond KM, Chaudry IH. Immune depression in polymicrobial sepsis: the role of necrotic (injured) tissue and endotoxin. Crit Care Med. (2000) 28:2849–55. doi: 10.1097/00003246-200008000-00004

76. Wichterman KA, Bae AE, Chaudry IH. Sepsis and septic shock—a review of laboratory models and a proposal. J Surg Res. (1980) 29:189–201. doi: 10.1016/0022-4804(80)90037-2

77. Parker SJ, Watkins PE. Experimental models of gram-negative sepsis. Br J Surg. (2001) 88:22–30. doi: 10.1046/j.1365-2168.2001.01632.x

78. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock. (2002) 17:463–7. doi: 10.1097/01.shk.0000023482.90026-9

79. Latifi SQ, O’Riordan MA, Levine AD. Interleukin-10 controls the pathways of laboratory models and a proposal. J Surg Res. (1980) 29:189–201. doi: 10.1016/0022-4804(80)90037-2

80. Diaz JA, Obi AT, Myers DDJ, Wrobleski SK, Henke PK, Mackman N, et al. SEPSIS, SD, Sepsis-1: 10 years of laboratory models and a proposal. J Clin Invest. (2002) 112:460–7. doi: 10.1172/JCI13019523

81. Mackman N. Triggers, targets and treatments for thrombosis. Nature. (2012) 498:662–7. doi: 10.1038/nature12395

82. Souza D, Robinson MJ, Zelenay S, Sancho D, Chakravarty P, Larsen R, et al. CLEC-2 signaling via Syk in myeloid cells can regulate inflammatory responses. Eur J Immunol. (2011) 41:3040–53. doi: 10.1002/eji.2011146141

83. Kuijpers MJ, Schulte V, Bergmeier W, Lindhout T, Brakebusch C, Offermanns S, et al. Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. FASEB J Off Publ Fed Am Soc Exp Biol. (2003) 17:685–7. doi: 10.1096/fj.02-0381

84. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad L, Zohlinhofer D, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med. (2003) 197:41–9. doi: 10.1084/jem.20020945

85. Mezger M, Nording H, Sauter R, Graf T, Heim C, von Bubnoff N, et al. Platelets and immune responses during thromboinflammation. Front Immunol. (2019) 10:1731. doi: 10.3389/fimmu.2019.01731

86. Gruner S, Prostredna M, Schulte V, Krieg T, Eckes B, Brakebusch C, et al. Multiple integrin-ligand interactions synergize in shear-resistant platelet adhesion at sites of arterial injury in vivo. Blood. (2003) 102:4021–4027. doi: 10.1182/blood-2003-05-1391

87. Mourao Sa D, Robinson MJ, Zelenay S, Sancho D, Chakravarty P, Larsen R, et al. CLEC-2 signaling via Syk in myeloid cells can regulate inflammatory responses. Eur J Immunol. (2011) 41:3040–53. doi: 10.1002/eji.2011146141
document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol. (2016) 111:41.
doi: 10.1007/s00395-016-0558-1
111. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol. (2016) 13:193–209. doi: 10.1038/nrcardio.2016.5
112. Matzinger P. The danger model: a renewed sense of self. Science. (2002) 296:301–5. doi: 10.1126/science.1071059
113. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Biochim Biophys Acta. (2013) 1835:1426–39. doi: 10.1016/j.bbadis.2013.04.021
114. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, de Mey er SF, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. (2012) 10:136–44. doi: 10.1111/j.1538-7836.2011.04544.x
115. Martinod K, Demers M, Fuchs TA, Wang SL, Brill A, Gallant M, et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci USA. (2013) 110:13674–9. doi: 10.1073/pnas.1301591110
116. Albadawi H, Oklu R, Raackle Malley RE, O’Keefe RM, Torg P, Cerny NR, et al. Effect of DNase I treatment and neutrophil depletio on acute limb ischaemia-reperfusion injury in mice. J Vasc Surg. (2016) 64:848–93. doi: 10.1016/j.vasurg.2015.01.031
117. Longstaff C, Letendre J-A, Goggs R. Concentrations of plasma nucleosomes but not cell-free DNA are prognostic in dogs following Trauma. Front Vet Sci. (2018) 5:180. doi: 10.3389/fvets.2018.00180
118. Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell. (2010) 140:619–30. doi: 10.1016/j.cell.2010.02.014
119. Michelwiska S, McColl A, Rossi AG, Megson IL, Dransfield I. Clearance of dying cells and autoimmunity. Autoimmunity. (2007) 40:267–73. doi: 10.1080/089169307013575208
120. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull. (2004) 70:71–86. doi: 10.1093/bmb/ldi025
121. Poulent M, Semple JW, Bollinger J, Cloutier N, Cognasse F, Boilard E, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. (2014) 124:2173–83. doi: 10.1182/blood-2014-05-573543
122. Qin C, Gu J, Qian H, Liu R, Xu F, Li Y, et al. Potential mechanism of post-acute aortic dissection inflammatory responses: the role of miRNA from activated platelets. Cardiovasc. (2016) 135:228–35. doi: 10.1159/000446870
123. Carestia A, Davis RP, Davis L, Jenne CN. Inhibition of immunothrombosis does not affect pathogen capture and does not promote bacterial dissemination in a mouse model of sepsis. Platelets. (2019) 31:925–31. doi: 10.1177/0953731019704711
124. Yang S, Qi H, Kan K, Chen J, Xie H, Guo X, et al. Neutrophil extracellular traps promote hypercoagulability in patients with sepsis. Shock. (2017) 47:132–9. doi: 10.1097/SHK.0000000000001741
125. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost. (2011) 9:2313–21. doi: 10.1111/j.1538-7836.2011.04465.x
126. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. (2012) 32:1777–83. doi: 10.1161/ATVBAHA.112.242589
127. Gould TJ, Vu TT, Stafford AR, Dwivedi DJ, Kim PY, Fox-Robichaud AE, et al. Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis. Arterioscler Thromb Vasc Biol. (2015) 35:2544–53. doi: 10.1161/ATVBAHA.115.306035
128. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SHC, Weitz JI, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. (2014) 34:1977–84. doi: 10.1161/ATVBAHA.114.304114
129. Jovic J, Longstaff C, Szabo L, Forkas AZ, Varga-Szabo VJ, Tanka-Salamon A, et al. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost. (2015) 113:1289–98. doi: 10.1160/TH14-08-0669
130. Gollomp K, Kowalska MA, Poncz M, Gollomp K, Kim M, Johnston I, et al. Neutrophil accumulation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun. (2019) 10:1322. doi: 10.1038/s41467-019-09180-7
131. Ueki S, Melo RCN, Ghiran I, Spencer LA, Dvorak AM, Weller PF. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood. (2013) 121:2074–83. doi: 10.1182/blood-2012-05-432088
132. Letendre J-A, Goggs R. Concentrations of plasma nucleosomes but not cell-free DNA are prognostic in dogs following Trauma. Front Vet Sci. (2018) 5:180. doi: 10.3389/fvets.2018.00180
133. Kaufman J, Bronkhorst AJ, Badenhorst CPS, Pretorius PJ. The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. Biomed Res Int. (2018) 93:1649–83. doi: 10.1155/2018/12413
151. Mazurov A V, Titaeva E V, Khaspekov GA, Storozhilova AN, Spiridonova VA, Kopylov AM, et al. Characteristics of a new DNA aptamer, direct inhibitor of thrombin. *J Exp Biol Med.* (2011) 150:422–5. doi: 10.1007/s10517-011-1158-6

152. Spiridonova VA, Novikova TM, Sizov VA, Shashkovskaya VS, Titaeva E V, Dobrovolsky AB, et al. DNA aptamers to thrombin exosite I. structure-function relationships and antithrombotic effects. *Biochemistry.* (2019) 84:1521–8. doi: 10.1134/S0006297919120113

153. O’Sullivan BP, Linden MD, Frelinger AL III, Barnard MR, Spencer-Manzon M, Morris JE, et al. Platelet activation in cystic fibrosis. *Blood.* (2005) 105:4635–41. doi: 10.1182/blood-2004-06-2098

154. Sturm A, Hebestreit H, Koenig C, Walter U, Grossmann R. Platelet proinflammatory activity in clinically stable patients with CF starts in early childhood. *J Cyst Fibros.* (2010) 9:179–86. doi: 10.1016/j.jcf.2009.12.004

155. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. *J Biol Chem.* (2003) 278:30725–31. doi: 10.1074/jbc.M301838200

156. Stead RJ, Barradas MA, Mikhailidis DP, Jeremy JY, Hodson ME, Batten JC, et al. Platelet hyperaggregability in cystic fibrosis. *Prostaglandins Leukot Med.* (1987) 26:91–103. doi: 10.1016/0262-1746(87)90104-1

157. Ciabattoni G, Davi G, Colliura M, Iapichino L, Pardo F, Ganci A, et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. *Am J Respir Crit Care Med.* (2000) 162:1195–201. doi: 10.1164/ajrccm.162.4.9911071

158. Falco P, Bertola A, Brighen S, Cavallo F, Boccadoro M, Palumbo A. Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. *Hematol J Off J Eur Haematol Assoc.* (2004) 5:456–7. doi: 10.1038/sj.thj.6200404

159. Gregory SH, Sagnimeni AJ, Wing EJ. Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. *J Immunol.* (1996) 157:2514–2520.

160. Tomkins AJ, Schleicher N, Murtha L, Kaps M, Levi CR, Nedelmann M, et al. Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke. *Exp Transl Stroke Med.* (2015) 7:2. doi: 10.1186/s13231-014-0014-y

161. Watson BD, Prado R, Veloso A, Brunschwig J-P, Dietrich WD. Cerebral blood flow restoration and reperfusion injury after ultraviolet laser-facilitated middle cerebral artery recanalization in rat thrombotic stroke. *Stroke.* (2002) 33:428–434. doi: 10.1161/hs0202.102730

162. Ge L, Zhou X, Ji W-J, Lu R-Y, Zhang Y, Zhang Y-D, et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. *Am J Physiol Heart Circ Physiol.* (2015) 308:H500–9. doi: 10.1152/ajpheart.00381.2014

163. Bakker EM, Tiddens HAWM. Pharmacology, clinical efficacy and safety of recombinant human DNase in cystic fibrosis. *Expert Rev Respir Med.* (2007) 1:317–29. doi: 10.1586/17476348.1.3.317

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.